CurrentPremera BluecrossPolicy 2.01.16

Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions

Defines medical necessity and investigational uses for recombinant platelet-derived growth factor (becaplermin) and autologous platelet-rich plasma (PRP) for wound healing and other non-orthopedic indications for Premera Bluecross members and treating providers.

Policy Summary

PayerPremera Bluecross

PolicyRecombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions

Policy CodePolicy 2.01.16

Change TypeNo material changes

Effective DateApr 1, 2026

Next Review DateNov 1, 2026

Key ActionObtain prior authorization and document transcutaneous PO2 ≥30 mm Hg, ulcer stage (III/IV), and participation in a wound management program when requesting becaplermin.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2specific covered indications for becaplermin

all non-orthopedicPRP stance — investigational for

30 mm Hgmin TcPO2 for becaplermin

stage III/IVrequired ulcer depth

0232T, G0460/G0465, P9020codes listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

manyongoing trials listed

Coverage Criteria and Evidence Summary

Becaplermin - Medically Necessary Criteria

Recombinant PDGF (becaplermin) may be considered medically necessary as an adjunct to standard wound management when ALL of the following for the indicated ulcer type are met:

Diabetic neuropathic ulcer candidates: For neuropathic diabetic ulcers extending into subcutaneous tissue: adequate tissue oxygenation demonstrated by transcutaneous partial pressure of oxygen (TcPO2) >= 30 mm Hg on the foot dorsum or at the ulcer margin; full-thickness ulcer (stage III or IV) extending through the dermis into subcutaneous tissues; participation in a wound management program that includes sharp debridement, pressure relief (non-weight bearing), and infection control; therapy typically applied once daily for up to 20 weeks or until healed.TcPO2 >= 30 mm Hg; full-thickness (stage III or IV)

Application may be performed by the individual in the home; dosing depends on ulcer size; document participation in a wound management program.

Pressure ulcer candidates: For pressure ulcers extending into subcutaneous tissue: full-thickness ulcer (stage III or IV) extending through the dermis into subcutaneous tissues; ulcer located in an anatomic site that can be off-loaded for the duration of treatment; albumin concentration > 2.5 dL; total lymphocyte count > 1,000/μL; normal values of vitamins A and C; participation in a wound management program is required; therapy typically applied once daily for up to 20 weeks.Albumin >2.5 dL; total lymphocyte count >1,000/μL; full-thickness (stage III or IV)

Document ability to off-load pressure for duration of treatment and required laboratory parameters.

PRP - Investigational

Autologous platelet-rich plasma (PRP) and other blood-derived autologous preparations for non-orthopedic indications:

PRP for non-orthopedic indications: Use of autologous PRP and other blood-derived autologous preparations is considered investigational for all non-orthopedic indications, including but not limited to acute, chronic, and non-healing wounds, surgical wounds, and a broad array of other conditions (e.g., alopecia, sexual dysfunction, assisted reproductive uses, facial and vulvovaginal rejuvenation).n/a

Evidence is limited by small trials, heterogeneous and nonstandard PRP preparations and protocols, and methodological flaws that preclude concluding improvement in net health outcome.

Evidence insufficiency across non-orthopedic indications

Summary of coverage-relevant evidence statements (no criteria for coverage are provided in this section; evidence characterized):

General evidence summary: Across non-orthopedic indications (including alopecia, assisted reproductive technology, erectile dysfunction, facial rejuvenation, Peyronie’s disease, stress urinary incontinence, and vulvovaginal atrophy), the evidence base is composed mainly of small randomized trials, observational studies, and systematic reviews that are heterogeneous, often low quality, and lack standardized PRP preparation methods and treatment protocols; therefore the evidence is insufficient to determine that PRP improves net health outcomes for these indications.

Common limitations include small sample sizes, risk of bias, variable or absent control groups, unreported platelet/growth factor concentrations, and short follow-up durations.

Medicare Coverage with Evidence Development (CED)

CMS covers autologous PRP for chronic non-healing diabetic wounds under specific conditions

CMS CED criteria: Autologous PRP may be covered under Medicare Coverage with Evidence Development when the patient has a chronic non-healing diabetic, pressure, and/or venous wound and is enrolled in a qualifying clinical research study that prospectively evaluates outcomes using validated methods (for example: complete wound healing; return to previous function; reduction in wound size or healing trajectory).Duration: up to 20 weeks for diabetic wounds when PRP is prepared by devices with FDA-cleared indications for exuding cutaneous wounds

Coverage beyond 20 weeks for diabetic wounds and coverage for other wound types is determined by local Medicare Administrative Contractors (MACs); the clinical study must meet CMS-specified requirements.

Other applications of recombinant platelet-derived growth factor (becaplermin) beyond the specified diabetic neuropathic and pressure ulcer indications are considered investigational. The policy explicitly lists examples including ischemic ulcers, venous stasis ulcers, and ulcers not extending through the dermis into subcutaneous tissue as investigational uses of becaplermin.

For non-orthopedic uses of platelet-rich plasma (PRP), the policy notes substantial variability and insufficiency in the evidence base. Studies frequently have small sample sizes, lack controls or standard reference protocols, and do not consistently report key preparation details (platelet concentration, leukocyte content, activation method). This heterogeneity limits comparability across trials and undermines conclusions about clinical effectiveness.

The National Institute for Health and Care Excellence (NICE) guidance (2019) is cited stating that neither autologous PRP gel nor platelet-derived growth factors should be offered for the treatment of diabetic foot ulcers, reflecting an explicit recommendation against these interventions in that context.

Policy history documents coding and editorial updates over time. Notably, CPT code 0232T was added in 2010 and later coding edits removed codes Q4102 and Q4103 as not applicable. The history also records an interim review on 12/01/25 and a further annual update on 04/01/26, including updates to HCPCS code descriptors for G0460 and G0465.

Overall, the policy takes an investigational stance for PRP across non-orthopedic applications: autologous PRP and related blood-derived preparations are considered investigational and therefore not medically necessary for all non-orthopedic indications, including a broad list of cosmetic, reproductive, sexual health, and wound-related uses.

For the non-orthopedic conditions reviewed (e.g., alopecia, assisted reproductive uses, erectile dysfunction, facial rejuvenation, Peyronie’s disease, stress urinary incontinence, vulvovaginal atrophy), the evidence is characterized as insufficient to determine an improvement in net health outcome. The body of literature is dominated by small RCTs, observational studies, and systematic reviews with methodological limitations and inconsistency in outcomes, preventing firm conclusions about clinical benefit.

Professional society guidance provides cautionary context: the American College of Physicians (ACP) historically favored other dressings over PDGF-containing products due to cost and limited evidence, and the Association for the Advancement of Wound Care (AWWC) concluded that growth factors are not indicated for pressure ulcers and that platelet-derived growth factor has shown no significant effect on venous ulcer healing or recurrence in cited guidance.

The policy was updated during an interim review on 12/01/25 to add additional conditions for which PRP is considered investigational. The history notes that these conditions were added during an approved interim review (November 11, 2025); specifics of those added conditions are recorded in the policy update but are not enumerated in this excerpt.

Procedure and Supply Codes

CPT codesCPT

0232T

Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed.

HCPCS codesHCPCS

G0460	Autologous platelet rich plasma (PRP) or other blood-derived product for nondiabetic chronic wounds/ulcers, (includes, as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment).
G0465	Autologous platelet rich plasma (PRP) or other blood-derived product for diabetic chronic wounds/ulcers, using an FDA-cleared device for this indication, (includes, as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment).

Other HCPCS / supply codesHCPCS

P9020	Platelet rich plasma, each unit.
S0157	Becaplermin gel 0.01%, 0.5 gm.
S9055	Procuren or other growth factor preparation to promote wound healing (Please note that Procuren may no longer be available, but this code is used to report other growth factor preparations that promote wound healing).

Regulatory / device contextmixed

No codes listed

Referenced procedure codes and historical coding changesHCPCS | CPT | mixed

G0460	HCPCS code descriptor updated in policy
G0465	HCPCS code descriptor updated in policy
0232T	CPT code previously added to policy

Transcutaneous partial pressure of oxygen (TcPO2) — threshold value

TcPO2 threshold>= 30 mm Hg (measured on the foot dorsum or at the ulcer margin)

Measurement siteFoot dorsum or at the margin of the ulcer

ContextRequired for diabetic neuropathic ulcers considered for becaplermin as documentation of adequate tissue oxygenation

Ulcer depth/stage requirement for becaplermin

Ulcer depth/stage requirementFull-thickness ulcer (stage III or IV) extending through the dermis into subcutaneous tissue

Applicable ulcer types

Prior Authorization, Documentation, and Operational Guidance

Prior Authorization

Prior Authorization Required

Prior authorization is required for listed wound and growth factor treatments when coverage is subject to benefit limits or when codes indicate high-utilization therapies. Providers must verify member benefits and obtain prior authorization when the intervention is outside clearly defined coverage criteria or when local coverage determinations (LCDs/MACs) or CMS national decisions impose enrollment or documentation requirements.

Affected codes include but are not limited to CPT 0232T (PRP injection), HCPCS G0460, G0465 (autologous PRP for chronic wounds), P9020 (PRP unit), S0157 (becaplermin gel), S9055 (other growth factor preparations).
G0460/G0465 descriptors were updated; consult the member's benefit and prior authorization rules for applicability and any code-specific authorization processes.

Prior Authorization

Prior Authorization Recommended for PRP (Non‑Orthopedic)

Prior authorization is recommended for platelet-rich plasma (PRP) when used for non‑orthopedic indications because evidence is limited and preparation methods are heterogeneous. When authorization is sought for PRP outside diabetic chronic wound indications, include thorough clinical rationale and documentation of prior standard treatments.

Background and Context

Blood-derived growth factors encompass both recombinant PDGF (becaplermin) — a laboratory-produced PDGF gel FDA-approved for select diabetic neuropathic lower-extremity ulcers — and autologous PRP, a point-of-care concentrate prepared from a patient’s own blood. Becaplermin is indicated as an adjunct to standard wound care for specific neuropathic diabetic and pressure ulcers that meet selection criteria, whereas PRP preparations vary widely in composition and preparation and are evaluated separately across numerous non-orthopedic indications.

Definitions and Terms

Recombinant platelet-derived growth factor (becaplermin) definition

DefinitionRecombinant platelet-derived growth factor (becaplermin) — a laboratory-produced PDGF-BB topical gel (Regranex) used as an adjunct to standard wound care to increase complete healing of lower-extremity diabetic neuropathic ulcers that extend into subcutaneous tissue, with labeled indication and warnings as described in product labeling.

FormulationTopical gel (Regranex) containing recombinant PDGF-BB

Indication summaryApproved for lower-extremity diabetic neuropathic ulcers that extend into subcutaneous tissue and have adequate blood supply, used as an adjunct to debridement, pressure relief, and infection control

Platelet-rich plasma (PRP) definition — preparation and activation

DefinitionPlatelet-rich plasma (PRP) — an autologous platelet concentrate suspended in plasma prepared from centrifuged autologous blood; exposure to thrombin and calcium chloride degranulates platelets and polymerizes fibrin to create a platelet gel for topical or surgical adjunctive use.

Policy Summary

PayerPremera Bluecross

PolicyRecombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions

Policy CodePolicy 2.01.16

Change TypeNo material changes

Effective DateApr 1, 2026

Next Review DateNov 1, 2026

Key ActionObtain prior authorization and document transcutaneous PO2 ≥30 mm Hg, ulcer stage (III/IV), and participation in a wound management program when requesting becaplermin.

SourceLink

On This Page

Neuropathic diabetic ulcers and pressure ulcers that extend into subcutaneous tissue

Documentation noteMust be documented as part of required clinical documentation for becaplermin use

Albumin concentration requirement

Albumin concentration requirement> 2.5 dL

Clinical contextRequired for pressure ulcers being considered for becaplermin

DocumentationAlbumin >2.5 dL must be recorded in the clinical documentation supporting becaplermin use

Total lymphocyte count requirement

Total lymphocyte count requirement> 1,000/µL

Clinical contextRequired for pressure ulcers being considered for becaplermin

DocumentationTotal lymphocyte count >1,000/µL must be recorded in the clinical documentation supporting becaplermin use

PRP for alopecia, stress urinary incontinence, vulvovaginal atrophy, assisted reproductive technology, and other non‑orthopedic uses is considered investigational or of insufficient evidence in many cases; prior authorization helps ensure appropriate use.
Document prior nonoperative and conservative therapies tried, durations, and objective outcome measures before PRP is considered.

Prior Authorization

Clinical Study Enrollment May Be Required (CMS)

When CMS coverage with ‘coverage with evidence development’ (CED) or other research enrollment requirements applies, autologous PRP for chronic non‑healing wounds may be covered only when the patient is enrolled in an approved clinical study that meets CMS criteria. Providers must confirm study eligibility and document enrollment in the prior authorization submission.

CMS requires prospective clinical study enrollment for coverage of autologous PRP for chronic non‑healing diabetic, venous, and pressure wounds under its 2012 NCD (and subsequent revisions).
For diabetic chronic wounds, CMS in 2021 limited covered duration to up to 20 weeks when prepared by FDA‑cleared devices for exuding cutaneous wounds; coverage beyond 20 weeks is determined by local MACs.

Documentation Required

Expect Detailed PRP Preparation & Protocol Documentation

Expect detailed PRP preparation and protocol documentation to accompany any authorization or claim for PRP. Because PRP products and methods vary widely, submissions must describe how the PRP was prepared and applied to permit medical necessity review.

Provide platelet concentration (baseline and post‑processing), platelet dose/volume delivered, leukocyte (WBC) and RBC content if available, activation method used (if any), device/manufacturer, centrifugation parameters, and number/interval of treatments.
Include clinical procedure details: injection sites, image guidance if used, total units (P9020) or per‑treatment coding (0232T), and accompanying wound care measures.

Denial Risk

Off‑label and High‑Use Risk (Becaplermin & Growth Factors)

Becaplermin and other growth factor therapies carry off‑label and high‑use risk. Use as an adjunct to, not a replacement for, standard wound care. Excessive or off‑label use may lead to utilization management actions, prior authorization denials, or request for additional justification.

Becaplermin (Regranex) is FDA‑approved for specific full‑thickness diabetic foot ulcers as an adjunct; use outside those indications increases risk of denial.
Monitor cumulative product use (manufacturer tube sizes noted in Additional Guidelines) — the 2008 boxed warning history and subsequent label changes necessitate careful risk/benefit documentation for prolonged use or multiple tubes.

Note

Medicare / Local Coverage Risk

Medicare and local coverage determinations can differ from commercial plan policy. Providers should verify Medicare rules and be aware that MACs may set different coverage limits for PRP and growth factor therapies.

CMS NCD and subsequent decision memos govern autologous PRP coverage for certain chronic wounds; local MACs determine coverage for many other wounds and for durations beyond CMS limits.
For Medicare beneficiaries, confirm whether local MACs require additional documentation or limit coverage for non‑diabetic chronic wounds.

Documentation Required

Verify Member Benefits and Document

Always consult member benefits and document benefit verification in the record. Coverage is determined by the member's contract; medical policy is a guide but not a substitute for benefit verification.

Contact customer service or review the member benefit booklet to determine plan‑specific limits, prior authorization pathways, and whether the policy applies to the member's product (note: this medical policy does not apply to Medicare Advantage).
Document benefit check results, authorization numbers, and any plan‑specific prerequisites in the medical record and in the authorization submission.

Documentation Required

Treatment Course and Prerequisite Conservative Care

Prior to initiating PRP or growth factor therapy, document an adequate course of conservative and standard wound care and relevant clinical prerequisites. Treatments are typically considered adjunctive to comprehensive wound management.

Document participation in a wound management program that includes sharp debridement, infection control, offloading/pressure relief, and appropriate dressings.
For becaplermin: demonstrate adequate tissue oxygenation (TcPO2 ≥ 30 mm Hg at ulcer site), full‑thickness ulcer staging (stage III/IV), nutritional/lab thresholds (albumin >2.5 g/dL, total lymphocyte count >1,000/µL, normal vitamins A and C where applicable), and duration/response to prior standard care.
Typical treatment frequency for autologous PRP or growth factor applications is once daily up to a CMS‑specified maximum (e.g., becaplermin guidance: once daily topical application; PRP procedural cadence varies by protocol).

Prior Authorization

Consider Standard Therapy Before PRP/Growth Factors

Consider and document that standard therapies should be attempted prior to PRP or growth factor use when applicable. Guidelines favor alternative dressings and standard wound care measures over growth factors in many wound types.

ACP and wound care society guidance recommend established dressings (hydrocolloid, foam) and standard wound care measures; growth factors are often not indicated for pressure or venous ulcers.
For conditions such as SUI, VVA, alopecia, and ART, document prior standard/established therapies and their outcomes before PRP is used as an experimental or adjunctive option.

Documentation Required

Adjunctive Use — Must Complement Standard Wound Care

Growth factors and PRP should be used as adjuncts to comprehensive wound care, not as standalone treatments. Authorization and medical necessity reviews will expect concurrent standard care documentation and rationale for adjunctive use.

Indicate how the growth factor or PRP integrates with debridement, offloading, infection control, and appropriate dressings.
For becaplermin, the FDA‑approved indication specifies use as an adjunct to good ulcer care practices; similar expectations apply to other growth factor therapies.

Preparation stepsPrepared from centrifuged autologous blood; activation commonly with thrombin and calcium chloride to release growth factors and form a gel

Variability noteDifferent preparation systems and devices yield variable platelet and protein concentrations, affecting clinical comparability

Platelet-rich plasma (alternate entry)

Alternate/concise termPlatelet-rich plasma (PRP) — autologous platelet concentrate in plasma used topically or as adjunct to surgery

Key propertiesSource: patient’s own blood; contains PDGF, transforming growth factors, and VEGF; used to deliver growth factors to wounds

DistinctionDistinct from fibrin sealants (which are platelet-poor and derived from pooled donors); PRP is autologous and platelet-rich

Ongoing clinical trials (Table 1 entries) — NCT identifiers

NCT identifiers (selected from Table 1)NCT07117955; NCT06645379; NCT03474718; NCT05850611; NCT05996614; NCT06281483; NCT05181748

Trial status noteListed trials are ongoing or planned per Table 1; completion dates vary (some continue into 2027–2028)

Indications representedTrials cover varied indications including Peyronie’s disease, reproductive medicine, androgenic alopecia, diabetic foot ulcer combination therapies, skin graft take, and chronic non-healing skin ulcers

PRP regulatory/tissue processing context

Regulatory contextPRP and other blood products fall under FDA regulations for human cells and tissues (21 CFR parts 1270 and 1271); many PRP preparation systems have received 510(k) clearance for point-of-care concentration devices.

Exemption/clarificationCertain blood products are exempt from traditional FDA pathways; to date the FDA has not attempted to regulate activated PRP specifically

ImplicationUse of different devices and preparation methods leads to variable platelet/protein concentrations which affects study comparability and regulatory interpretation

Becaplermin (Regranex) — FDA approval summary

FDA approval summaryRegranex Gel (becaplermin) approved in 1997 for lower-extremity diabetic neuropathic ulcers that extend into subcutaneous tissue and have adequate blood supply, to be used adjunctively with standard ulcer care.

Label limitationsEfficacy not evaluated for ulcers that do not extend into subcutaneous tissue or for ischemic diabetic ulcers; not intended for wounds closing by primary intention.

Boxed warning history2008 black box warning added for increased cancer mortality with use of three or more tubes in a postmarketing study; warning language revised in 2018 to remove specific 'cancer mortality' phrasing—use with caution in patients with known malignancy.

Autologous blood-derived products / PRP general description

General descriptionAutologous blood-derived products/PRP — platelet-rich preparations made from a patient’s own blood used topically or as a dressing component to deliver growth factors to wounds.

ComponentsIncludes concentrated platelets, associated growth factors (PDGF, TGF, VEGF), and fibrin matrix when activated; composition varies by preparation method.

Clinical use noteUsed as topical application or adjunct to surgery; evidence for non-orthopedic indications is heterogeneous and often insufficient